Pharmacological preconditioning with the cellular stress inducer thapsigargin protects against experimental sepsis.
Animals
Anti-Inflammatory Agents
/ therapeutic use
Cytokines
/ physiology
Disease Models, Animal
Humans
Male
Mice
Mice, Inbred C57BL
Oxidative Stress
/ drug effects
Pre-Exposure Prophylaxis
Protective Agents
/ therapeutic use
RAW 264.7 Cells
Sepsis
/ drug therapy
Thapsigargin
/ therapeutic use
Toll-Like Receptor 4
/ metabolism
4-Phenylbutyric acid (CID:4775)
Pharmacological preconditioning
Protein translational efficiency
Sepsis
Systemic inflammation response
Thapsigargin
Thapsigargin (CID: 446378)
mTOR
Journal
Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
27
09
2018
revised:
12
12
2018
accepted:
19
12
2018
pubmed:
24
12
2018
medline:
4
9
2019
entrez:
24
12
2018
Statut:
ppublish
Résumé
Previous studies have shown that pretreatment with thapsigargin (TG), a cellular stress inducer, produced potent protective actions against various pathologic injuries. So far there is no information on the effects of TG on the development of bacterial sepsis. Using lipopolysaccharides- and cecal ligation/puncture-induced sepsis models in mice, we demonstrated that preconditioning with a single bolus administration of TG conferred significant improvements in survival. The beneficial effects of TG were not mediated by ER stress induction or changes in Toll-like receptor 4 signaling. In vivo and in cultured macrophages, we identified that TG reduced the protein production of pro-inflammatory cytokines, but exhibited no significant effects on steady state levels of their transcriptions. Direct measurement on the fraction of polysome-bound mRNAs revealed that TG reduced the translational efficiency of pro-inflammatory cytokines in macrophages. Moreover, we provided evidence suggesting that repression of the mTOR (the mammalian target of rapamycin) signaling pathway, but not activation of the PERK (protein kinase R-like endoplasmic reticulum kinase)-eIF2α (eukaryotic initiation factor 2α) pathway, might be involved in mediating the TG effects on cytokine production. In summary, our results support that pharmacological preconditioning with TG may represent a novel strategy to prevent sepsis-induced mortality and organ injuries.
Identifiants
pubmed: 30579975
pii: S1043-6618(18)31472-5
doi: 10.1016/j.phrs.2018.12.017
pii:
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Cytokines
0
Protective Agents
0
Tlr4 protein, mouse
0
Toll-Like Receptor 4
0
Thapsigargin
67526-95-8
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
114-122Informations de copyright
Copyright © 2018 Elsevier Ltd. All rights reserved.